CD95 ligand expression as a mechanism of immune escape in breast cancer

Immunology

Volumn 99, Issue 1, 2000, Pages 69-77

  Moers, C ^b   Warskulat, U ^b   Even, J ^a   Niederacher, D ^b   Beckmann, M W ^b   Muschen M ^a,c  

^a INSTITUT PASTEUR   (France)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN;

ANTIGEN BINDING; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; BREAST CANCER; CELL DIVISION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LYMPHOCYTE ACTIVATION; PRIORITY JOURNAL;

ANTIGENS, CD95; APOPTOSIS; BREAST NEOPLASMS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FAS LIGAND PROTEIN; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; JURKAT CELLS; LYMPHOCYTE COUNT; MEMBRANE GLYCOPROTEINS; PROTEIN ISOFORMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 0033980144     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2567.2000.00921.x     Document Type: Article

References (29)

1. 1. Watanabe-Fukunaga R., Brannan C.I., Copeland N.G., Jenkins N.A. & Nagata S. (1992) Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356, 314.
2. 2. Leithäuser F., Dhein J., Mechtersheimer G. et al. (1993) Constitutive and induced expression of Apo-1, a new member of the Nerve Growth Factor/ Tumor Necrosis Factor Receptor superfamily, in normal and neoplastic cells. Lab Invest 69, 415.
3. 3. Cheng J., Zhou T., Liu C. et al. (1994) Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 263, 1759.
4. 4. Muschen M., Warskulat U., Peters-Regehr T., Bode J.G., Kubitz R. & Häussinger D. (1999) Involvement of CD95 (Apo-1/ Fas) ligand expressed by rat Kupffer cells in hepatic immunoregulation. Gastroenterology 116, 666.
5. 5. Strand S., Hofmann W.J., Hug H. et al. (1996) Lymphocytes apoptosis induced by CD95 (Apo-1/Fas) ligand expressing tumor cells - a mechanism of immune evasion? Nature Med 2, 1361.
6. 6. Tanaka M., Suda T., Haze K. et al. (1996) Fas ligand in human serum. Nature Med 2, 317.
7. 7. Kayagaki N., Kawasaki A., Ebata T. et al. (1995) Metalloproteinase-mediated release of human Fas ligand. J Exp Med 182, 1777.
8. 8. Tanaka M., Itai T., Adachi M. & Nagata S. (1998) Downregulation of Fas ligand by shedding. Nature Med 4, 31.
9. 9. Müschen M., Warskulat U., Moers C., Simon D., Even J. & Häussinger D. (1998) Derangement of the CD95-system in a case of Churg-Strauss vasculitis. Gastroenterology 114, 1351.
10. 10. Müschen M., Warskulat U., Even J. et al. (1999) Involvement of soluble CD95 in Churg Strauss syndrome. Am J Pathol 1999; 155, 915.
11. 11. Keane M.M., Ettenberg A., Lowrey G.A., Russel E.K. & Lipkowitz S. (1996) Fas expression and function in normal and malignant breast cell lines. Cancer Res 56, 4791.
12. 12. Cai Z., Stancou R., Körner M. & Chouaib S. (1996) Impairment of Fas-antigen expression in Adriamycin-resistant but not in TNF-resistant MCF-7 tumor cells. Int J Cancer 68, 535.
13. 13. Müschen M., Moers C., Warskulat U. et al. (1999) CD95 ligand expression in dedifferentiated breast cancer. J Pathol 1999; 189, 378.
14. 14. O'Connell J., O'Sullivan G.C., Collins J.K. & Shanahan F. (1996) The Fas Counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 184, 1075.
15. 15. Hahne M., Rimoldi D., Schröter M. et al. (1996) Melanoma cell expression of CD95 (Apo-1/Fas) ligand: implications for tumor immune escape. Science 274, 1363.
16. 16. Hug H. (1997) Fas-mediated apoptosis in tumor formation and defense. Biol Chem 378, 1405.
17. 17. Seino K.I., Kayagari N., Okumura K. & Yagita H. (1997) Antitumor effect of locally produced CD95 ligand. Nature Med 3, 165.
18. 18. Arai H., Chan S.Y., Bishop D.K. & Nabel G.J. (1997) Inhibition of the alloantibody response by CD95 ligand. Nature Med 3, 843.
19. 19. Schnürch H.G., Stegmüller M., Vering A., Beckmann M.W. & Bender H.G. (1994) Growth inhibition of xenotransplanted carcinomas. Eur J Cancer 30, 491.
20. 20. Pannetier C., Delassus S., Darche S., Saucier C. & Kourilsky P. (1993) Quantitative titration of nucleic acids by enzymatic amplification reactions run to saturation. Nucl Acids Res 21, 577.
21. 21. Josien R., Douillard P., Guillot C. et al. (1998) A critical role for transforming growth factor-β (TGF-β) in donor transfusion-induced allograft tolerance. J Clin Invest 102, 1920.
22. 22. Müschen M., Warskulat U., Douillard P., Gilbert E. & Häussinger D. (1998) Regulation of CD95 (Apo-1/Fas) receptor and ligand expression by lipopolysaccharide and dexamethasone in parenchymal and nonparenchymal rat liver cells. Hepatology 27, 200.
23. 23. Müschen M., Warskulat U., Schmidt B, Schulz W.A. & Häussinger D. (1998) Regulation of CD95 (Apo-1/Fas) ligand and receptor expression in human embryonal carcinoma cells by IFNγ and all trans-retinoic acid. Biol Chem 379, 1083.
24. 24. Gavrieli Y., Sherman Y. & Ben-Sasson S.A. (1992) Identification of programmed cell death in situ via specific labelling of nuclear DNA fragmentation. J Cell Biol 119, 493.
25. 25. Beutler B. & Cerami A. (1984) Cachectin and tumor necrosis factor as two sides of the same biological coin. Nature 320, 584.
26. 26. Beckmann M.W., Niederacher D., Schnürch H.G., Gusterson B. & Bender H.G. (1997) Multistep carcinogenesis of breast cancer and tumor heterogeneity. J Mol Med 75, 429.
27. 27. Moers C., Warskulat U., Müschen M. et al. (1998) Regulation of CD95 (Apo-1/ Fas) ligand and receptor expression in squamous cell carcinoma by interferon γ and Cisplatin. Int J Cancer 80, 564.
28. 28. Rabinovich H., Reichert T.E., Kashii Y., Gastmann B.R., Bell M.C. & Whiteside T.L. (1998) Lymphocyte apoptosis induced by Fas ligand-expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes. J Clin Invest 101, 2579.
29. 29. Pannetier C., Even J. & Kourilsky P. (1995) T-cell repertoire diversity and clonal expansions in normal and clinical samples. Immunol Today 16, 176.